Pasotuxizumab

Also Known As:

AMG 212; BAY 2010112

Networked: 4 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Bispecific Antibodies: 968
        Pasotuxizumab: 4
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Bispecific Antibodies: 968
        Pasotuxizumab: 4
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Bispecific Antibodies: 968
        Pasotuxizumab: 4

Experts

1.	Finnern, Ricarda: 2 articles (01/2021 - 12/2012)
2.	Kufer, Peter: 2 articles (01/2021 - 12/2012)
3.	Stienen, Sabine: 2 articles (01/2021 - 03/2016)
4.	Kischel, Roman: 2 articles (03/2016 - 12/2012)
5.	Ajavon-Hartmann, Antoinette: 1 article (01/2021)
6.	Bargou, Ralf C: 1 article (01/2021)
7.	Boix, Oliver: 1 article (01/2021)
8.	Buck, Andreas: 1 article (01/2021)
9.	Chatterjee, Manik: 1 article (01/2021)
10.	Deschler-Baier, Barbara: 1 article (01/2021)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 01/01/2021 - "Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings." 01/01/2021 - "Aim: We report results of a first-in-human study of pasotuxizumab, a PSMA bispecific T-cell engager (BiTE®) immune therapy mediating T-cell killing of tumor cells in patients with advanced castration-resistant prostate cancer. " 12/01/2012 - "Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens." 01/01/2021 - "Conclusion: Data support pasotuxizumab safety in advanced castration-resistant prostate cancer and represent evidence of BiTE monotherapy efficacy in solid tumors. " 12/01/2012 - "For treatment of patients with prostate cancer (PCa), we developed a novel T cell-engaging (BiTE) antibody designated AMG 212 or BAY2010112 that is bispecific for prostate-specific membrane antigen (PSMA) and the CD3 epsilon subunit of the T cell receptor complex. "
2.	Neoplasms (Cancer) 12/01/2012 - "No effects on tumor growth were observed in the absence of human T cells or AMG 212/BAY2010112. " 12/01/2012 - "The subcutaneous (s.c.) formation of tumors from PC-3-huPSMA cells in NOD/SCID mice was significantly prevented by once daily intravenous (i.v.) injection of AMG 212/BAY2010112 at a dose level as low as 0.005 mg/kg/d. " 01/01/2021 - "Aim: We report results of a first-in-human study of pasotuxizumab, a PSMA bispecific T-cell engager (BiTE®) immune therapy mediating T-cell killing of tumor cells in patients with advanced castration-resistant prostate cancer. " 03/01/2016 - "In solid tumor indications, three BiTE(®) antibody constructs have been tested in phase 1 studies so far: anti-EpCAM BiTE(®) AMG 110, anti-CEA BiTE(®) MEDI-565/AMG 211, and anti-PSMA BiTE(®) BAY2010112/AMG 212. " 01/01/2021 - "Conclusion: Data support pasotuxizumab safety in advanced castration-resistant prostate cancer and represent evidence of BiTE monotherapy efficacy in solid tumors. "
3.	Bites and Stings (Sting) 12/01/2012 - "On the basis of these preclinical results, AMG 212/BAY2010112 appears as a promising new BiTE antibody for the treatment of patients with PSMA-expressing PCa." 12/01/2012 - "In addition to Chinese hamster ovary cells stably expressing human or cynomolgus monkey PSMA, T cells redirected by AMG 212/BAY2010112 also lysed human PCa cell lines VCaP, 22Rv1, MDA PCa 2b, C4-2, PC-3-huPSMA, and LnCaP at half maximal BiTE concentrations between 0.1 and 4 ng/mL (1.8-72 pmol/L). " 03/01/2016 - "In solid tumor indications, three BiTE(®) antibody constructs have been tested in phase 1 studies so far: anti-EpCAM BiTE(®) AMG 110, anti-CEA BiTE(®) MEDI-565/AMG 211, and anti-PSMA BiTE(®) BAY2010112/AMG 212. " 12/01/2012 - "Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens." 01/01/2021 - "Conclusion: Data support pasotuxizumab safety in advanced castration-resistant prostate cancer and represent evidence of BiTE monotherapy efficacy in solid tumors. "

Related Drugs and Biologics

1.	Pasotuxizumab
2.	Antigens
3.	Epithelial Cell Adhesion Molecule
4.	T-Cell Antigen Receptors (T-Cell Receptor)

Related Therapies and Procedures

1.	Castration
2.	Therapeutics